(Q37598900)

21 August 2017

1 reference

title

Sex-specific differences in side effects of psychotropic drugs: genes or gender? (English)

1 reference

21 August 2017

Sara Haack

1

1 reference

21 August 2017

Angela Seeringer

2

1 reference

21 August 2017

Petra A Thürmann

3

1 reference

21 August 2017

Thomas Becker

4

1 reference

21 August 2017

Julia Kirchheiner

5

1 reference

21 August 2017

publication date

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

1511-1526

1 reference

Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Do women have more adverse drug reactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender differences in pharmacological response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The influence of sex on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Time course of clinical response to venlafaxine: relevance of plasma level and chirality

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

How important are gender differences in pharmacokinetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Effects of age and sex on olanzapine plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Chart-recorded psychiatric diagnoses in women giving birth in California in 1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Effects of Gender and Age on Plasma Levels of Clozapine and Its Metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Quetiapine serum concentrations in psychiatric patients: the influence of comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender differences in a sample of schizophrenic outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Pharmacokinetic Drug Interactions with Oral Contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender effects in pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Sex, ethnicity, and antipsychotic medication use in patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender and the use of neuroleptics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Good tolerability equals good results: the patient's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Are gender differences important for the clinical effects of antidepressants?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Special aspects of neuropsychiatric illness in women: with a focus on depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender differences in depression and antidepressant pharmacokinetics and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Weight effects associated with antipsychotics: a comprehensive database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Genetics of antipsychotic treatment emergent weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Genetic aspects of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The human obesity gene map: the 2005 update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Weight gain with clozapine compared to first generation antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Clozapine and body mass change.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Weight gain among patients on clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Prevalence of metabolic syndrome among inpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Increased plasma leptin in antipsychotic-naïve females with schizophrenia, but not in males.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Homocysteine levels in newly admitted schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Atypical antipsychotic drugs and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Treatment considerations in women with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

A study of serum prolactin levels in schizophrenia: comparison of males and females

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Hyperprolactinaemia and antipsychotic therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The effects of phenothiazines on endocrine function: II. Effects in men and post-menopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Dopamine antagonists and the development of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Sexual side effects of novel antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The neurobiology of sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addi

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Physician-induced torsade de pointes--therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Effects of gender on cardiac arrhythmias.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Sex difference in risk of torsade de pointes with d,l-sotalol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Increased propensity of women to develop torsades de pointes during complete heart block

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Concomitant use of antipsychotics and drugs that may prolong the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Tardive dyskinesia: who is at risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Tardive dyskinesia and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender differences in tardive dyskinesia: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Sight and insight: brain dopamine receptor occupancy by neuroleptics visualised in living schizophrenic patients by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Brain receptors for antipsychotic drugs and dopamine: direct binding assays

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Tardive dyskinesia and new antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Pharmacological profile of HWA-131, a novel antiinflammatory agent with immunomodulating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender differences in treatment response to sertraline versus imipramine in chronic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Antidepressant-induced sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Thyroid abnormalities during lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Lithium-associated clinical hypothyroidism. Prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Lithium treatment and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Sodium valproate in the treatment of resistant epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Sodium valproate: monotherapy and polytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Adverse effects of valproate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Bodyweight gain and anticonvulsants: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Valproate, weight gain and carbohydrate craving: a gender study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Polycystic ovary syndrome in women using valproate: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Reproductive function and risk for PCOS in women treated for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Valproate, bipolar disorder and polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Occurrence of thrombocytopenia in psychiatric patients taking valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Blood dyscrasias induced by psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Gender differences in adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Rash from antiepileptic drugs: influence by gender, age, and learning disability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Changes in body mass index for individuals with and without schizophrenia, 1987–1996

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

Schizophrenia and the risk for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.102

21 January 2018

Identifiers

DOI

10.2217/PGS.09.102

1 reference

21 August 2017

1 reference